Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Standard Medicines
Drugs
Locations
Clinical Specialty
41-60 of 1,782 trials

Chronic Kidney Disease: Amiloride Treatment Study

We are investigating whether the diuretic amiloride can help protect kidney function in people with chronic kidney disease. The study looks at its effects on kidney health and inflammation.

Chronic Kidney Disease≤3 monthsEfficacy phase (II)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineNephrology

Systemic Lupus Erythematosus: Deucravacitinib Study

We are evaluating a new medication, deucravacitinib, for individuals with active systemic lupus erythematosus. The study aims to determine if it is more effective than a placebo in reducing disease symptoms and improving overall health.

Active Systemic Lupus Erythematosus1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementRheumatology

Post-Cardiac Arrest Shock: High-Dose Vitamin C Study

We are investigating whether early intravenous high-dose vitamin C can help patients who have suffered a cardiac arrest and are in shock. The study aims to see if this treatment reduces the need for blood pressure support and improves survival and recovery.

Cardiac Arrest6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesCardiologyInternal Medicine

Diabetic Neuropathic Pain: Incobotulinumtoxin-A Injections

We are studying whether injections of incobotulinumtoxin-A can help relieve pain in people with diabetic neuropathic pain in their lower extremities. The trial will also look at how this treatment affects daily activities and overall quality of life.

Diabetic Peripheral Neuropathic Pain6-12 monthsEfficacy phase (II)Standard MedicinesDiabetologyEndocrinologyNeurology

Salivary Duct Carcinoma: Dutasteride with Combined Androgen Blockade

We are studying whether adding dutasteride to standard therapy helps patients with recurrent or metastatic salivary duct carcinoma. The trial also looks at safety and quality of life for those receiving this new treatment.

Salivary Duct CarcinomaEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesOncology

Heart Attack Treatment: Methylprednisolone Study

We are investigating whether a steroid given before hospital treatment can reduce heart damage in patients with a heart attack. This study aims to improve heart function and decrease inflammation after the event.

Heart Attack1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCardiologyInternal Medicine

Advanced Breast Cancer: Ribociclib Study

We are examining how well Ribociclib works for patients with advanced breast cancer and what factors may affect its effectiveness. The study also looks at quality of life and any side effects experienced during treatment.

Hormone Receptor Positive HER2 Negative Breast Cancer>2 yearsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesPartially RemoteOncology

Hematologic Cancers: Continued Treatment with Tafasitamab

We are providing ongoing treatment for patients with blood cancers who have previously received Tafasitamab. This study focuses on evaluating the safety of continued use of this medication.

Hematological MalignancyConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Morphine Study in Obesity and Sleep Apnea Patients

We are investigating how obesity and obstructive sleep apnea influence the effects of morphine for pain relief. This research aims to improve pain management for patients, especially those having bariatric surgery.

Obesity Surgery>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementEndocrinologyInternal MedicineOrthopedics and TraumatologyOtolaryngologyPsychiatry

Acute Myeloid Leukemia: New Treatments for Children and Adolescents

We are exploring different therapies for children and adolescents with acute myeloid leukemia to see if they improve survival and treatment outcomes. This includes testing new drugs alongside standard chemotherapy.

Acute Myeloid Leukemia>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyPediatrics

Eosinophilic Gastritis: Dupilumab Treatment Study

We are investigating how well dupilumab works for adults and adolescents with eosinophilic gastritis, with or without eosinophilic duodenitis. The study will also look at the safety and side effects of this treatment.

Eosinophilic Gastritis1-2 yearsEfficacy phase (II)Post-Trial Drug AccessStandard MedicinesPartially RemoteGastroenterologyInternal Medicine

Multiple Myeloma: Linvoseltamab Treatment Study

We are investigating the safety and effectiveness of linvoseltamab in patients with newly diagnosed multiple myeloma who have not yet received treatment. This study will help us understand how well this new therapy works for different patient groups.

Multiple MyelomaEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteHematologyOncology

Advanced Non-Small Cell Lung Cancer: Datopotamab Deruxtecan and Pembrolizumab

We are studying a new treatment combination for patients with advanced non-small cell lung cancer who have not had prior therapy. The goal is to see if this combination works better than standard treatments in improving survival and reducing disease progression.

Advanced Non-small Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Arrhythmic Mitral Valve Prolapse: Flecainide and Metoprolol Study

We are studying whether adding flecainide to metoprolol can better reduce irregular heartbeats in patients with arrhythmic mitral valve prolapse. This trial aims to assess the safety and effectiveness of this combination treatment.

Mitral Valve Prolapse>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Prostate Cancer: Neoadjuvant Treatment with [177Lu]Lu-PSMA-617

We are studying a new method of delivering a targeted treatment for men with high-risk prostate cancer before surgery. The goal is to evaluate its safety and how well it works compared to standard approaches.

High-Risk Prostate Cancer3-6 monthsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncologyUrology

Atrial Fibrillation: Colchicine Study

We are investigating whether colchicine can help prevent the return of atrial fibrillation in patients scheduled for heart rhythm treatment. We will also look at its effects on heart health and quality of life.

Atrial Fibrillation and Atrial Flutter>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesCardiology

Post-Traumatic Stress Disorder: Testing New Therapy

We are studying a new therapy called reconsolidation therapy for people with severe PTSD. This trial compares it to standard treatment and looks at whether adding propranolol can improve outcomes.

Post-Traumatic Stress Disorder≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesPsychiatry

Type 1 Diabetes: INVITED Trial on Flu Vaccine

We are studying whether influenza vaccination can help protect insulin-producing cells in individuals with early type 1 diabetes. This research aims to find new ways to support diabetes management.

Type 1 Diabetes>2 yearsEfficacy phase (II)Standard MedicinesEndocrinologyInfectious Diseases

Aspirin for Preventing Preeclampsia in First-Time Pregnant Women

We are studying whether daily aspirin can help prevent preeclampsia and improve pregnancy outcomes in women who are pregnant for the first time after assisted reproductive technology. This trial compares aspirin to a placebo to see which is more effective.

Preeclampsia>2 yearsConfirmation phase (III)Monitoring phase (IV)≤5 visitsStandard MedicinesPartially RemoteGynecology and Obstetrics

Merkel Cell Carcinoma: Pembrolizumab with Chemotherapy

We are studying a new treatment combining pembrolizumab with chemotherapy for patients with advanced Merkel cell carcinoma. The goal is to see if this combination is effective and safe for those who haven't been treated before.

Merkel Cell CarcinomaEfficacy phase (II)No PlaceboStandard MedicinesDermatologyOncology